Incidence of Intracranial Hemorrhage in Glioma Patients With Venous Thromboembolism Converted From LMWH to Apixaban
Public ClinicalTrials.gov record NCT04895553. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Glioma patients with history of venous thromboembolism (VTE) treated on low molecular weight heparin (LMWH) and who decided with their physician to convert to Apixaban (oral drug) will be enrolled into our study and will collect data regarding recurrent VTE and Intracranial hemorrhage and the incidence of these events.
Study identification
- NCT ID
- NCT04895553
- Recruitment status
- Terminated
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2021
- Primary completion
- Aug 4, 2022
- Completion
- Aug 4, 2022
- Last update posted
- Dec 1, 2022
2021 – 2022
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UC Davis Comprehensive Cancer Center | Sacramento | California | 95817 | — |
| Johns Hopkins | Baltimore | Maryland | 21287 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Glioma, Malignant trials
Other public records listing Glioma, Malignant. Sorted by last update posted; newest first. Not a recommendation.
- NCT04547777: Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma Recruiting
- NCT06397560: PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial Recruiting
- NCT05979064: Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM) Recruiting
- NCT05954858: Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma Recruiting
- NCT05271240: Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM Recruiting
- NCT07416188: Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04895553, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 1, 2022 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04895553 live on ClinicalTrials.gov.